Pharma
The companies first partnered in 2020 to develop a prescription digital therapeutic for schizophrenia. They said a treatment strategy for the condition "would benefit from a multi-product approach."
Under the multiyear strategic partnership Anumana will conduct a clinical-validation trial and seek FDA De Novo classification for the algorithm.
The collaboration will offer low-cost medications to employees and employers through a new platform dubbed EmsanaRx Plus.
The company said it will use the capital to hire for its commercial teams and advance development on new features.
Data containing accurate medication history and prescription fill insights can lead to better patient outcomes, says Dr. Colin Banas, CMO of health IT company DrFirst.
PointClickCare's senior health-focused datasets will help to influence Pfizer's decisions on new therapies.
Also, Syntekabio has launched its cloud service platform for AI drug discovery.
Transcarent announced it would expand into the pharmacy benefit space in September.
The multinational pharma company will now be able to access Tempus' de-identified patient data.
The company also announced a partnership with pharma giant Biogen that allows providers to submit enrollment forms for its multiple sclerosis drug Vumerity through the new platform.